Health Canada approves Servier’s VORANIGO for IDH-mutant glioma

Servier Canada has announced Health Canada's approval of VORANIGO for Grade 2 IDH-mutant glioma in adults and paediatric patients.

Related Posts

Novartis signs deal for Arvinas’ prostate cancer therapy

Apr 13, 2024

Forbion European Acquisition and enGene sign merger deal

May 18, 2023

Innovate UK grants funds for breast cancer therapy project

Feb 12, 2024